Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. (NASDAQ: VCYT) is a leader in genomic diagnostics, developing advanced solutions that transform patient care through precision medicine. This dedicated news hub provides investors and healthcare professionals with timely updates on the company’s financial performance, clinical advancements, and strategic initiatives.
Access official press releases, earnings reports, and regulatory filings in one centralized location. Track developments across key areas including oncology testing innovations, global expansion efforts, and partnerships with leading research institutions. Our curated collection ensures you stay informed about milestones that shape VCYT’s role in advancing evidence-based diagnostic technologies.
Discover updates on new product clearances, peer-reviewed study publications, and executive leadership announcements. This resource is designed to support data-driven decision-making for stakeholders monitoring the evolving landscape of molecular diagnostics. Bookmark this page for direct access to primary source materials and analysis of Veracyte’s market position.
Veracyte, Inc. (Nasdaq: VCYT) has shared new insights into thyroid tumor behavior derived from their extensive thyroid nodule database. Presenting at the American Thyroid Association Annual Meeting, researchers reviewed over 300 pathology reports, revealing a negative predictive value for low-risk nodules of 95%. The Afirma Genomic Sequencing Classifier (GSC) identified a higher malignancy risk of 15.3% in nodules with TSHR mutations, compared to <1.5% for benign classifications. These findings emphasize the potential for improved personalized treatment decisions.
Veracyte (NASDAQ: VCYT) presented key findings at the CHEST Annual Meeting 2022, demonstrating the clinical value of its Envisia Genomic Classifier and Percepta Nasal Swab tests. The Envisia test identified genomic patterns indicating progressive disease in patients with interstitial lung disease (ILD), showing a significant decline in lung function among positive cases. Meanwhile, initial data for the Percepta Nasal Swab test suggested improved risk stratification for lung cancer in patients with nodules. These innovations aim to enhance patient care and assist physicians in making informed treatment decisions.
Veracyte, Inc. (Nasdaq: VCYT) announced it will release its third quarter 2022 financial results on November 2, 2022, after market close. Management plans to host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a business update. The call will be available via webcast on the company's website. Veracyte focuses on improving patient care with advanced diagnostic tests that help avoid unnecessary procedures and reduce treatment time, with operations based in South San Francisco, California.
Veracyte (NASDAQ: VCYT) announced results from the VANDAAM Phase 2 clinical study, published in the Journal of the National Cancer Institute, highlighting the effectiveness of its Decipher Prostate Genomic Classifier. This genomic test may significantly enhance the identification of African American men with localized prostate cancer at risk for more aggressive disease. The study involved a balanced cohort of 226 men, showcasing that African American participants were over twice as likely to have higher Decipher scores compared to non-African American men. This advancement could help in reducing disparities in prostate cancer outcomes.
Veracyte, Inc. (NASDAQ: VCYT) has appointed Dr. John Leite as the new Senior Vice President and General Manager of Pulmonology & Market Access. Dr. Leite will oversee commercial activities for Veracyte’s lung portfolio, including the Percepta Nasal Swab test for lung cancer, prior to its broad commercialization. His extensive experience in the diagnostics industry, particularly in market development and strategy, is expected to significantly impact Veracyte's goals in addressing unmet needs in pulmonology and improving patient care in lung diseases.
Veracyte (NASDAQ: VCYT) announced findings from the Phase 3 STAMPEDE trial indicating that the Decipher Prostate Genomic Classifier is effective in predicting clinical outcomes for men with high-risk prostate cancer. The study found that the test can help determine which patients may benefit from intensified treatment with abiraterone acetate and prednisolone in addition to standard therapies. The company aims to expand the test's availability in the U.S. and internationally as an in vitro diagnostic.
Veracyte (NASDAQ: VCYT) announced findings at the European Respiratory Society International Congress 2022 indicating that the Envisia Genomic Classifier can predict which interstitial lung disease (ILD) patients, including those with idiopathic pulmonary fibrosis (IPF), are likely to decline with combination immunosuppressive therapy. The study, involving 135 patients, revealed that EGC-positive patients showed a lung function decline of 9.4% with the therapy, compared to 1.9% for EGC-negative patients. Veracyte plans to submit the Envisia IVD test for regulatory approval in Europe in 2023.
Veracyte (Nasdaq: VCYT) has announced that CEO Marc Stapley and CFO Rebecca Chambers will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13 at 2:55 p.m. Eastern Time. A live audio webcast of this presentation can be accessed on Veracyte's website, and a replay will be available for 90 days post-event. Veracyte is dedicated to improving patient care through advanced diagnostic tests, helping patients avoid unnecessary procedures and reducing time to appropriate treatments.
Veracyte (NASDAQ: VCYT) will present seven abstracts on its genomic tests for prostate and breast cancers at the ESMO Congress 2022 from September 9-13 in Paris. A notable highlight includes data from a post-hoc analysis of the Decipher Prostate test within the STAMPEDE trial, potentially expanding its use among advanced prostate cancer patients in the U.S. and abroad. Veracyte aims to enhance patient care through its diagnostic tests, which are designed to minimize risky procedures and ensure faster treatment decisions.
Veracyte (VCYT) announced findings showing that its immuno-oncology biomarkers can predict responses to CAR T-cell therapy in large B-cell lymphoma patients. Published in Nature Medicine, the study highlights the prognostic importance of the tumor microenvironment (TME) prior to treatment. Key results indicate that the Immunoscore CR and Immunosign 21 biomarkers are associated with improved survival rates following CAR T-cell therapy. These insights may enhance patient outcomes and inform clinical trials, demonstrating Veracyte's potential in advancing precision medicine.
